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Neurodegenerative diseases like Parkinson’s disease (PD) and
Alzheimer’s disease (AD) are considered disorders of multifac-
torial origin, inevitably progressive and having a long preclinical
period. Currently, the clinical diagnosis of PD can bemadewhen
motor symptoms occur, though the disease has originated several
years earlier. Furthermore, at its initial stages PD may be
confounded by other diseases, such as essential tremor, multiple
system atrophy (MSA) and progressive supranuclear palsy
(PSP). Similar to PD, the pathological process characteristic of
AD begins decades before the first symptoms of cognitive
dysfunctions, thus making it difficult to reliably identify
pathology based on the clinical phenotype alone. AD may share
clinical features with many other dementing disorders including
vascular dementia, dementia with Lewy bodies, PSP and others.
Therefore, the availability of biological markers or biomarkers
(BMs) for early disease diagnosis will impact the management
of AD and PD in several dimensions; it will 1) help to capture
high-risk individuals before symptoms develop, a stage where
prevention efforts might be expected to have their greatest
impact; 2) provide a measure of disease progression that can
be evaluated objectively, while clinical measures are much
less accurate; 3) help to discriminate between true AD or PD
and other causes of a similar clinical syndrome; 4) delineate
pathophysiological processes responsible for the disease; 5)
determine the clinical efficacy of novel, disease-modifying
(neuroprotective) strategies.
BMs have been defined as “cellular, biochemical or
molecular alterations that are measurable in the biological
media such as human tissues, cells or fluids”. BMs for
detection of neurodegenerative disorders can be divided
into three main categories: genetic, neuroimaging, and
biochemical. Normally, neuroimaging and biochemical
BMs mark the presence of pathology, while genetic markers
can only serve for risk assessment. Neurochemical BMs
measured in the periphery by means of proteomics/
metabolomics in blood plasma, CSF and other tissues,
may be useful adjuncts to imaging and clinical assessment
tools for AD and PD. They may also provide valuable
information about pathogenic mechanisms during clinical
testing of neuroprotective/disease modifying drugs, which
is especially relevant to personalized treatment.
Since both AD and PD have a long preclinical period, future
efforts should be focused on this time window to begin a
neuroprotective treatment. Early screening, detection, and
diagnosis of AD and PD will allow intervention with disease
modifying therapies at earlier stages and thus may potentially
improve clinical outcome. Large multicenter studies are
warranted to evaluate the diagnostic value of the combined
application of BMs with multiple modalities for prediction,
targeted prevention and evaluation of disease modifying
therapies in AD and PD.
ALZHEIMER ’S DISEASE: DIAGNOSTICS,
PROGNOSTICS AND THE ROAD TO PREVENTION
Grossman I
Cabernet Pharmaceuticals, USA
Alzheimer’s disease (AD) presents one of the leading
healthcare challenges of the 21st century, with a projected
world-wide prevalence of >107 million cases by 2025.
While biomarkers have been identified which may correlate
with disease progression or sub-type for the purpose of
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disease monitoring or differential diagnosis, dependable
prediction of late onset disease risk has not been available
until now. This deficiency in reliable predictive biomarkers,
coupled with the devastating nature of the disease, places
AD at a high priority for focus by predictive, preventive
and personalized medicine (PPPM). Recent data, discov-
ered using phylogenetic analysis, suggest that a variable
length poly-T sequence polymorphism in the TOMM40
gene, adjacent to the APOE gene, is predictive of risk
of AD age-of-onset. This finding has been confirmed
in several independent cohorts, thus offering hope for
reliable assignment of disease risk within a 5–7 year
window. This scientific finding is now being utilized in a
pharmacogenetic-enrichment global clinical trial for the
first AD preventative therapy. This clinical trial will also
prospectively validate the utility of this marker as a stand-
alone prognostic of incipient disease.
DISCOVERY, DEVELOPMENT, VALIDATION AND
QUALIFICATION OF MARKERS WITH CLINICAL
UTILITY TO THE DELAY OF ONSET OF
ALZHEIMER’S DISEASE CLINICALTRIAL
Roses AD
Duke University and Zinfandel Pharmaceuticals, Inc., USA
A novel clinical trial design is being used for the simul-
taneous development of a predictive test algorithm, a
companion genetic diagnostic [predictor] and testing the
efficacy of a drug to delay the onset of Alzheimer’s disease
(AD).
The TOMM40 gene encodes the translocase of the outer
mitochondrial membrane pore subunit, and is in linkage
disequilibrium with the APOE gene. The length of a poly-T
variant (“523”) within intron 6 of TOMM40 has been
shown to predict the age of onset of late onset Alzheimer’s
disease (LOAD). These data allow the design of a
prospective epidemiologic-ascertained longitudinal study
to assess the onset of neuropsychological signs of cognitive
impairment and the progression of clinical impairment. By
using the group predictions to segment subjects’ risk based
on their age, APOE genotype, and TOMM40-523 geno-
type, the positive and negative predictive values obtained
from placebo treated subjects can be computed at the end of
the study. These prospective data are necessary before the
data can be used as a prognostic test for the risk of disease
and its age of onset.
The design of the clinical study to assess the clinical utility
of a predictive algorithm provides the opportunity to
simultaneously perform a clinical trial. This trial will assess
whether a drug can delay onset of cognitive impairment of
the type leading to AD. The design of OPAL [Opportunity
to Prevent Alzheimer’s disease] was considered with the
FDAVoluntary Exploratory Data Submission group before
any drug was nominated and was determined to be a well-
designed pharmacogenetic-assisted clinical trial.
It is important to point out that the predictions proposed for
the study are simply being used to segment high and lower
risk groups for the purpose of evaluation of the predictive
value [both positive and negative] and the effect of a safe
drug for which there is a rationale to slow or prevent the
AD process. Clinical utility demands that the putative
predictive algorithms be tested before application in normal
individuals for so-called AD predictions. The study design
provides the opportunity to demonstrate that a drug delays
onset, so that the use of the clinical predictive data is more
than just a prediction, but an opportunity for preventive
therapy.
In January 2011, a partnership was established by Zinfandel
Pharmaceuticals, Inc. and Takeda Pharmaceuticals, Inc. to
develop pioglitazone, a drug approved for treatment of
diabetes mellitus, to delay the onset of AD. An up-to-date
report of the status of the trial, particularly concerning
the procedures for registering a companion diagnostic
[predictive] with a therapeutic agent, will be presented.
The first steps are: 1- engagement with the regulatory
authorities based on newly published regulatory guidelines;
2- identification of normal subject groups; and 3- organi-
zation of the resources for periodic neuropsychology testing
of hundreds of people at each study site for an extended
period of time.
NEW ANIMAL MODELS OF PROGRESSIVE
NEURODEGENERATION:TOOLSFOR IDENTIFYING
PRESYMPTOMATIC THERAPEUTIC TARGETS
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1Department of Biomedical Sciences, University of Prince
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Mental and neurological disorders are increasingly preva-
lent and constitute a major societal and economic burden
worldwide. The impact of these disorders has traditionally
been underestimated by epidemiological data that have
relied on mortality rather than morbidity. According to the
World Health Organization mental and neurological disor-
ders are responsible for only about 1% of deaths but
account for almost 11% of the global disease burden [http://
www.who.int/mental_health/neurology/en]. Further, due to
increased life expectancy and the ageing of general
populations in both developed and developing countries
this number is expected to rise to 14.7% by 2020. Many of
the most socially and economically devastating neurolog-
ical diseases and disorders are characterized by progressive
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neurodegeneration. Symptoms of many forms of progres-
sive disease often appear in late adolescence or early
adulthood and then become increasingly severe with
increasing age. The neurodegenerative process however,
usually begins long before the onset of clinically diagnosed
symptoms. Thus, in many cases a precipitating event
occurring much earlier in life, often around the time of
birth or in early childhood, appears to initiate a degenera-
tive cascade that proceeds undetected for some time prior to
the onset of clinical signs. Presymptomatic detection of
disease therefore represents a largely unexplored opportu-
nity for therapeutic intervention. This general concept is
depicted in Figure.
Understanding the aetiology, and initiation, of disease often
relies on animal models, as does the development of new
therapeutic strategies. But while there are a multitude of
animal models that mimic specific features of end-stage
disease for almost all neurological conditions, most of these
models have been created to identify new therapeutants to
alleviate symptoms, and hence do not allow study of the
development of disease. Understanding disease develop-
ment is the key to identifying early intervention strategies
consistent with the concept in Figure. There exists,
therefore, a largely unmet need to develop and exploit
animal models designed to understand the origins and
progression of neurological disease. This presentation
will introduce several examples of recently developed
and characterized animal models of progressive neurode-
generative disease. Further, it will explore the concept of
models that can be used to study co-morbidities between
end-stage disease states. Developing new predictive and
preventative therapeutic strategies, as well as identifying
novel and reliable biomarkers and drug targets for pre-
symptomatic intervention requires a paradigm-shift,
whereby the goal is to predict and treat generalized
neurologic dysfunction in the early stages rather than
focusing drug development on late-stage disease-defined
symptoms and palliative care.
RISKASSESSMENT INGLAUCOMADEVELOPMENT
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Particularities of the neurodegenerative disease Glaucoma
Neurodegenerative eye disease glaucoma is the second leading
cause of blindness with estimated 67 million patients world-
wide. Molecular pathomechanisms of glaucoma demonstrate
both a considerable overlap with and remarkable particularities
compared to other neurodegenerative disorders e.g. Alzheimer’s
disease. Identification of pathology-specific molecular-sets is
essential to develop advanced diagnostic approaches.
Glaucomatous optic neuropathy (GON) is characterised by
a combination of a loss of retinal ganglion cells and their
axons with disease typical optic nerve head (ONH) atrophy.
The aetiology of glaucoma and risk factors are only








– optic disc haemorrhages
– haemodynamics, others
Fig. 1. Risk factors in glaucoma and measurement of intra-ocular
pressure (IOP).
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IOP (intra-ocular pressure) is considered the most important
and only modifiable risk factor in glaucoma. Although elevated
IOP has been shown to be the major risk factor, there is a cohort
of patients, sometimes even at younger ages with normal IOP
developing normal-tension glaucoma (NTG).
Impact of vascular component and relevance of gene
expression patterns in blood for glaucoma pathology
Awealth of literature points to the potential importance of
haemodynamics in glaucoma pathology, but randomized
controlled trials are not yet available. Healthy individuals
with Vasospastic Syndrome demonstrate molecular profiles in
blood similar to those of glaucoma patients [1]. Particular
predisposition of vasospastic individuals to glaucoma is
discussed in the recent review [2].
Key molecular pathways affected by glaucoma pathology:
Sub-cellular imaging and expression patterns in blood as
the reliable platform for early/predictive diagnosis
Key molecular pathways affected by glaucoma pathology
have been recently summarized in the book specifically
dedicated to predictive diagnostics and personalized
treatment [3].
The majority of molecules altered in glaucoma belongs to
well-defined functional gene-groups which, altogether,
represent molecular pathways affected by the pathology:
stress response, apoptosis and DNA-repair, adhesion,
blood–brain-barrier-breakdown, tissue remodeling, tran-
scription regulation, multi-drug resistance and energy
metabolism.
Outlook
Currently a clinical application of the test is under
consideration, and a nanotechnology which should provide
a possibly easy and cheap routine application of the test is
under development. Possible types of molecular alterations
that can be considered for predictive glaucoma diagnosis
and corresponding detection technologies are summarized
in Table 1.
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Type of molecule Possible type of alteration Detection technology
Chromosomal DNA,
mitochondrial DNA
1. (Oxidative) damage* - Comet assay
2. Mutations* - Disease genomics
3. Polymorphism* - PCR, Restriction analysis, etc.
4. Methylation status of CpG islands** - Methylation-specific PCR
mRNA 1. Multiple alterations in expression patterns* - Disease transcriptomics:
Subtractive hybridization, Expression array,
Reverse-Transcriptase-PCR, Real-Time-PCR, etc.
2. Reduced mRNA editing - Reverse-Transcriptase-PCR
Proteins 1. Multiple alterations in expression patterns* - Disease Proteomics: 2D-PAGE, MALDI-TOF,
Western-blot, etc.
2. Posttranslational modification* - Western-blot, Activity tests
(e.g. Zymography for gelatinases)
3. Phosphorylation status* - Activity tests
4. Protein misfolding* - Activity tests
Metabolites (signaling molecules,
amino acids, plasma hormones, etc.)
Altered profiles* Disease Metabolomics: Comparative blood plasma
metabolites profiling, HPLC, Activity tests, etc.
Table 1. Types of glaucoma-specific molecular alterations that can be potentially used for development of advanced tools for early and predictive
diagnosis. Data taken from [4].
*Types of molecular alterations reported for glaucoma pathology.**Data indicating this kind of alteration collected in our laboratory, which,
however, have not been published until now.
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Treatment of amyotrophic lateral sclerosis (ALS) has
been fueled, in part, by frustration over the short-
comings of the symptomatic drugs available, since
these do not impede the progression of the disease.
Currently, over 150 different potential therapeutic
agents or strategies have been tested in preclinical
models of ALS. Unfortunately, therapeutic modifiers of
murine ALS have failed to be successfully translated
into strategies for patients, probably because of differ-
ences in pharmacokinetics of the therapeutic agents,
route of delivery, inefficiency of the agents to affect
the distinct pathologies of the disease or inherent
limitations of the available animal models. Given the
multiplicity of the pathological mechanisms implicated
in ALS, new therapies should consider the simulta-
neous manipulation of multiple targets. Additionally, a
better management of ALS therapy should include
understanding the interactions between potential risk
factors, biomarkers and heterogeneous clinical features
of the patients, aiming to manage their adverse events
or personalize the safety profile of these agents.
Indeed, novel therapeutic approaches employed in
preclinical models of ALS, including iron-binding brain
permeable pluripotential neuroprotective compounds,
gene therapy, cell replacement therapies or a combina-
tion of both can offer improved alternative therapies
for ALS. Another viable therapeutic approach is
transplantation of stem cells genetically engineered, or
otherwise induced to secrete various neurotrophic
factors, known for their role in survival, development
and maintenance of motor neurons. Additionally, it has
been considered that multimodal neuroprotective iron
chelating compounds that possess neuritogenic effect
and regulatory activity of neurotrophic factors, may
mediate a regeneration process of motor nerves, and
induce neuro-differentiation and sprouting of axons.
These therapeutic strategies take into account the
various challenging features of ALS and the interplay
of genetic and environmental risk factors, to provide
superior efficacy in translation from preclinical studies
to the clinic.
POPULATION IMAGING FOR DISEASE PREDICTION
AND PREVENTION
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Department of Radiology, Erasmus MC, University
Medical Center Rotterdam, The Netherlands
Imaging is fundamental to basic and applied life
sciences research. Life scientists use medical imaging
techniques to understand living systems at both the
molecular and the physiological level, from biological
model systems to patients. Imaging allows non- or
minimally-invasive assessment of structural and func-
tional changes in intact organisms that may reflect
specific pathology. Recent developments in image data
acquisition and analysis make it feasible to use these
techniques on a large scale. This makes it possible to
investigate specific pathophysiological substrates of
disease in a pre-symptomatic phase, in an epidemiolog-
ical context, and at the population level.
It is now widely recognized that we need biomarkers to
improve the accuracy of diagnoses early in the disease process
and to monitor changes in organs of individuals even before
the first clinical symptoms of disease manifest. Although
biochemical markers have promising value in the early stages
of diseases, many of them are non-specific and do not allow
localization of the ongoing functional and structural alter-
ations. Imaging biomarkers have a substantial contribution in
detecting, localizing, and determining the extent of disease.
Identifying imaging biomarkers and risk factors of pre-
symptomatic disease and developing of predictive models
for functional and structural alterations requires large, pro-
spective epidemiological studies in unselected populations in
which sub-clinical pathology can be assessed.
Population imaging is the large-scale application and
analysis of medical images in controlled population
cohorts. Population imaging aims to find imaging bio-
markers that allow prediction and early diagnosis of
diseases and preventive therapy. Population imaging will
provide further insight into what roles risk factors play, both
qualitatively and quantitatively, in the morphologic sub-
strates underlying disease development. Dedicated infra-
structures and large-scale collaborations are needed in order
to extract meaningful information from population imaging
studies. Correlation with outcomes and genetic information
may provide further insight into risk profiles and disease
prediction
A recent example is the increasing interest in cerebral
microbleeds. Imaging sequences were developed to
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increase the conspicuity of hemosiderin deposits in the
brain. These showed that such deposits, the so called
‘microbleeds’, are present in 20% of the elderly. They
are thought to reflect vessel fragility, on the basis of
either hypertensive vascular damage or amyloid angiop-
athy. A hypothesis that remains to be investigated is that
persons with microbleeds are at an increased risk of
symptomatic intracerebral hemorrhage. If true, the risk-
benefit ratio of anticoagulant therapy to prevent ische-
mic brain events would differ between persons with and
without co-existing microbleeds.
Population imaging has many potential areas of application
for disease prediction and prevention. Examples include
intima-media thickness of carotid artery for arteriosclerosis
detection, coronary calcium scoring for coronary artery
disease, size of the hypocampus in predicting neuro-
degeneration, etc. Imaging may become the key to
identifying people that could benefit from preventive
intervention for many more diseases. Additionally, struc-
tural and functional organ changes that reflect (incipient)
clinical disease can be used as outcome measures in a
variety of studies, including clinical trials and etiologic
research as well as diagnostic and prognostic studies.
THE ROLE OF OPTICAL COHERENCE TOMOGRA-
PHY IN PREDICTING AND MONITORING DISEASE
ACTIVITY IN MS
Dörr J, Paul F
Charité Berlin, Germany
Increasing evidence documents that neuronal and
axonal damage within the central nervous system
(CNS) contributes substantially to the development of
permanent disability in multiple sclerosis (MS). How-
ever, in vivo quantification and longitudinal monitoring
of neurodegenerative processes remain a challenging
task. Whole brain atrophy expressed by brain paren-
chymal fraction (BPF) is a frequently used MRI-based
surrogate parameter for neurodegeneration within the
CNS and an inverse relation of BPF and disability
progression has been consistently demonstrated. How-
ever, all MRI-based measures of brain atrophy have
some important disadvantages. Besides limited avail-
ability, time consumption and costs, crucial confounders
such as hydration status, inflammation, demyelination
and age have to be accounted for. Thus, a need for
reliable, inexpensive and easily assessable complemen-
tary surrogate markers for neuroaxonal degeneration
still remains. During the past two decades, optical
coherence tomography (OCT) has emerged into a
fascinating tool for the non invasive and reproducible
in vivo studying of retinal neuroaxonal damage. In MS
patients, OCT has been consistently shown to detect
thinning of the peripapillary retinal nerve fiber layer
(RNFL) which is most probably due to a diffuse
damage of retinal axons and at least in part indepen-
dent of a previous optic neuritis (ON). Moreover, the
determination of total macular volume (TMV) has been
suggested as a marker for neuronal loss in MS patients.
Therefore, OCT might be a valuable tool for quantifi-
cation and monitoring of both axonal and neuronal
damage in MS and thus a surrogate marker of disease
activity and progression. However, data on association
between retinal nerve fiber layer thickness (RNFLT) and
MS-determining parameters such as disease severity and
disease duration are still inconsistent. Whereas some
studies found an association between RNFLT and
disease duration both parameters were not related in
other studies. Furthermore, data regarding the relation
between OCT parameters and MRI measures for neuro-
degeneration are not yet consistent and a consensus on
the most relevant parameter has yet to be reached. In
this contribution, we will summarize and update the
current data on the value of OCT in predicting and
monitoring disease activity in MS and delineate the
future work which remains to be done in order to
improve the utility of OCT as a valuable predictive
biomarker in MS and other neuroinflammatory and
neurodegenerative diseases.
URO- FECAL DISORDERS AND DYSPRAXIA.
FMRI AS AN USEFULTOOL FOR PERSONALIZED
MEDICINE. PRELIMINARY RESULTS
Ventimiglia B, Tsirgiotis A, Motta S, Puglisi T, Trovato G
European Neurosciences Study Group, Servizio di Neuro
Urologia ed Urodinamica, Dipartimento delle Specialità
Medico Chirurgiche, Università di Catania, Italy
Introduction: Developmental dyspraxia is due to an
impairment of the motor learning function; 4–5% of
patients have also associated uro-fecal incontinence,
enuresis and encopresis. This disease can affect planning
of movements and co-ordination as a result of brain
messages not being accurately transmitted to the body. It
does not affect overall intelligence or ability, but just
particular aspects of development: dyspraxia affects the
planning of what to do and how to do it. It is associated
with problems of perception, language and thought. It
could be due to a partial or absolute deficiency of the
mirror neurons development, which is responsible for
the differential maturation of motor chains in the
cortices.
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Learning and consolidation of the experience seems to
occur through the formation of neural circuits that allow a
mirror action done with as little effort as possible and lower
neuronal metabolic intracerebral expenditure. Dyspraxic
patients seem unable to form the mirror neuronal circuits
through the common factors of experience and then, every
day, it is as if they were to compare with a world known for
the first time. For example, they often do not speak well
because they cannot store the association between the
sound of a word to the thing or person of reference.
The control of urination, the neuronal circuits that allow us
to urinate as desired, is a very long corticalization process
(bowel control occurs long after the child learns to talk or
walk).
Functional magnetic resonance imaging can be used as an
experimental paradigm for exploring mirror neurons activ-
ity and coordination during voluntary or imitative acts.
The purpose of this preliminary study was to assess if
Functional Magnetic Resonance Imaging (fMRI) can
predict the impairment of the process of formation of
mirror neurons in Dyspraxic patients with uro-fecal
incontinence with the goal of managing them earlier with
a personalized approach.
Materials and methods: In 2010, we have studied six patients,
four males and two females, 18–24 years old, referred for
enuresis and encopresis and already diagnosed as dyspraxic.
All patients were studied by routine laboratory tests and by
Holter Electroencephalography with night urodynamic as-
sessment. All subjects were examined with full and empty
bladder by fMRI and multi-stage analysis with coincidence;
auditory and visual evocative tests of micturition were
administered. After 6 months of medical and rehabilitation
treatment patients were again studied by fMRI.
Results: All the six patients showed by fMRI uncoordinated
and abnormal activation of F5cortical centers, suggesting
mirror neurons impairment: two patients (Group A) had
detrusor overactivity, nocturnal enuresis and encopresis,
and were treated by parasympathicolytic agents and
behavioral physical and motor therapy, with bladder
retraining. Four patients without urodynamic abnormalities
but with enuresis and encopresis were treated by desmo-
pressin and behavioral physical and motor therapy. At time
1, after treatment in Group A encopresis and enuresis
disappeared and fMRI normalization of mirror response
was observed. In group B, three patients achieved conti-
nence in wakefulness, encopresis decreased, but enuresis
remained unchanged. One patient had no benefit. In this
group B- no responders patients - the fMRI showed no
difference from the baseline while in the other two patients
BOLD (Blood-oxygen-level dependence) hyperactivation
appeared very late.
Fig. 1 fMRI imaging of the onset the micturition reflex a: normal
patient, b: dispraxic patient.
Conclusion: In some dispraxic patient but not all, behav-
ioral and pharmacological therapy appear to have an effect
on the formation of mirror neuronal circuits, reasonably for
existence of different level and typology of disease.
These findings suggest that activity within the mirror neuron
system is severely impaired in patients with dyspraxia and
enuresis-encopresis and provide a neural basis for therapeut-
ical interventions and novel rehabilitation treatments. The
fMRI can be useful for diagnosis and prediction of develop-
mental dyspraxia because there is the possibility of a
differentiation between type of dispraxia and prognosis.
A personalized approach to diagnosis and treatment of this
patients should include a urological anamnesis with a
neuro-urological approach and could help in the prevention
of severe psychological distress and complication.
PERSONALIZATION OF MULTIPLE SCLEROSIS
TREATMENTS: THE CONCEPT OF CHELATION
THERAPY APPROACH
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Multiple Sclerosis (MS) is one of the most common chronic
diseases affecting the CNS with 2.5 million cases world-
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wide. The highest incidence in white women; three-quarters
of cases present between ages 15 and 45. Symptoms are:
fatigue, pain, visual impairment, imbalance, cognitive
change, numbness, depression, spasticity, weakness, change
in coordination, dysphagia, dizziness. Symptoms can be
mild or severe, ongoing or intermittent, disabling or tolerable.
It is characterized by acute multifocal demyelination. Envi-
ronmental factors triggering chronic inflammatory response
are unknown. The concomitant neuronal damage may be
mediated by free radicals.
The traditional therapy: high-dose glucocorticoids, Glatiramer
acetate (Copaxone), high-dose IFN beta 1 a (Rebif), high-
((Betaseron; Extavia) and low-dose IFN beta 1b (Avonex),
Natalizumab (Tysabri) and Mitoxandrone (Novantrone). All of
these treatments have varying side effects and potential toxicity.
Our hypothesis is that Aluminium toxicity is involved in
the pathogenesis of MS. Aluminium is a common metal in
the earth but not known to perform any function in the
body: it is thought to be a cellular toxin and can damage the
CNS. It is a potent environmental neurotoxin that induces
locomotor, cognitive and behavioral disability. The best
method of measuring the presence of toxic metals is EDTA
Chelation Therapy.
Chelation Therapy consists of intravenous administration of
a synthetic amino acid, ethylene diamine tetracetic acid
(EDTA), given in combination with other substances. EDTA
has been found to be effective in removing toxic metals
from the body and EDTA chelation therapy was approved
for this use by the Food and Drug Administration in 1953.
At physiological pH EDTA removes toxic metals deposited
in the body (body burden).
The fact is that some foods are health-promoting, others are
health-depleting. Personalized treatment protocols base on a
combination of chelation therapy for removing toxic
metals, integration of vitamins, minerals and supplements
to improve detoxification, essential fatty acids for anti-
inflammatory activity and diet correction by personalized
programs. Glutathione (GSH) is a tripeptide molecule and
plays a central role in cellular function, detoxification and
protection from damage caused by free radicals. It is
produced and circulates naturally in the body, neutralizing
free radicals and removing environmental poisons. Defi-
ciency of it contributes to oxidative stress and plays a key
role in the pathogenesis of many diseases. Long chain
Omega 3 fatty acids (EPA and DHA) are molecules that
cannot be synthesized by humans. EPA and DHA reduce
the levels of pro-inflammatory eicosanoids and promote
wellness. Common sources include fish oil and some
plant oils such as flax-seed. Reduction of high glycemic
pro-inflammatory foods and regular physical activity are
very important for the success by our protocol. Regular
exercises increase the secretion of growth hormone
(GH), stimulate the release of endorphins and decrease
the risk of osteoporosis.
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